Behavioral and Pharmacological Reconsolidation Interference in Misophonia

NCT05928689 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 141

Last updated 2024-10-16

No results posted yet for this study

Summary

One of the core processes presumably underlying misophonia - a condition characterized by decreased tolerance for specific sounds - is associative learning. Using behavioral, computational, and neural analyses of emotional learning and memory processes to understand the unknown behavioral and neural mechanisms underlying misophonia's associative learning and memory, the study team will evaluate whether interference with the reconsolidation of a reactivated misophonia memory with propranolol can alleviate aversive reaction to misophonia-related cues.

Conditions

  • Misophonia

Interventions

DRUG

Propranolol Hydrochloride tablet

Single dose of 40 mg propranolol tablet

BEHAVIORAL

Reminder

Reactivation of misophonia trigger memory

BEHAVIORAL

Counterconditioning

Counterconditioning will consist of presentation of misophonia cues paired with monetary rewards.

DRUG

Placebo

Matching placebo tablet

Sponsors & Collaborators

Principal Investigators

  • Daniela Schiller, PhD · Icahn School of Medicine at Mount Sinai

  • James Murrough, MD, PhD · Icahn School of Medicine at Mount Sinai

  • Laili Soleimani, MD, Msc · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-02
Primary Completion
2024-09-30
Completion
2024-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05928689 on ClinicalTrials.gov